United Therapeutic (UTHR) Stock Price, Quote & News

Company Profile

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated wit...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 301 608 9292

Website: www.unither.com

Address:

1000 Spring Street, Silver Spring, United States

SuperGreenToday Apr. 30 at 7:54 PM

$UTHR Share Price: $571.22 Contract Selected: Nov 20, 2026 $580 Calls Buy Zone: $51.00 – $63.00 Target Zone: $81.43 – $99.53 Potential Upside: 51% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

stevemano Apr. 29 at 7:34 PM

$UTHR I hear Martin let Smokey mountain mist get into his eyes ! With the mist krap! https://youtu.be/HzckwQad9p4?si=XVBTBUw89wnXCs5k

0 · Reply

clan Apr. 29 at 6:50 PM

$UTHR The Ralinopag oral version just ain't gonna cut it, @ItzaFugazi . Them Unitherians are gonna need the Technosphere/DPI version in order to avoid all them there nasty, patient-quitting, adverse effects. Whatever they decide to call it, it'll be more effective than the current gut-busting, colon-blowing pill. For the good of all Mannkind! ... and $MNKD

0 · Reply

clan Apr. 29 at 10:22 AM

$UTHR Next week, it will be interesting to hear CEO Martin(e) and CFO Benkowitz discuss the growth of Tyvaso DPI Sales Q4/Q1 and the color they may give to maintaining continued future growth of DPI; now 2 months removed from their hasty, chaotic, vague, and somewhat crontradicting previous comments. It will certainly effect $MNKD share price (positively). #blockbuster #secondmolecule # "cleanup on aisle 26" $NVS

0 · Reply

stevemano Apr. 29 at 9:43 AM

$MNKD perhaps this the $UTHR creature was in its form. Its day will come.

0 · Reply

grampslol Apr. 28 at 11:41 PM

I'm okay with $MNKD closing pennyland again...after all, it's Afizzle...lol $UTHR $SPY $BX $IBB

0 · Reply

DopeyCJ Apr. 28 at 7:32 PM

$BX $IBB $MNKD $UTHR what about being down more than 50% on the last 3 months?

1 · Reply

clan Apr. 28 at 7:28 PM

$MNKD I'm okay with MNKD being up over 20% in the last month. 🤑 More up and to the right coming.↗️ #pdufa #afrezza #autoinjector $BX $IBB $UTHR

0 · Reply

clan Apr. 28 at 2:42 PM

$MNKD RBC Capital certainly to upgrade and increase after FDA pediatric approval for Afrezza. #additionalindication #inflectionpoint #recordrevenues #cashgenerator $BX $UTHR $SPY

0 · Reply

grampslol Apr. 28 at 12:41 AM

Pennyland $MNKD 592 total employees 292 employees classified as sales, general and administrative 31 Vice Presidents 225 executive directors, senior managers and directors ... Top heavy Csuite Flop drug Coughing issues identified by partner $UTHR so they're moving on to SMI and away from this Afizzle...

0 · Reply

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

Apr 22, 2026, 7:00 AM EDT - 8 days ago

United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026

Apr 20, 2026, 6:30 AM EDT - 10 days ago

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

Apr 8, 2026, 7:00 AM EDT - 22 days ago

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

Mar 30, 2026, 7:00 AM EDT - 4 weeks ago

United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

Mar 11, 2026, 6:14 PM EDT - 7 weeks ago

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

Mar 9, 2026, 1:00 PM EDT - 7 weeks ago

United Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 7 weeks ago

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program

Mar 3, 2026, 7:00 AM EST - 2 months ago

United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference

Mar 2, 2026, 2:30 PM EST - 2 months ago

United Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:30 AM EST - 2 months ago

United Therapeutics Transcript: Study result

Mar 2, 2026, 6:38 AM EST - 2 months ago

United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study

Mar 2, 2026, 6:30 AM EST - 2 months ago

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

Feb 26, 2026, 1:54 PM EST - 2 months ago

These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings

Feb 25, 2026, 9:00 AM EST - 2 months ago

United Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 6:30 AM EST - 2 months ago

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026, 7:00 AM EST - 2 months ago

United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 7:00 AM EST - 2 months ago

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026

Jan 26, 2026, 7:00 AM EST - 3 months ago

United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure

Jan 22, 2026, 7:00 AM EST - 3 months ago

United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

Jan 12, 2026, 4:30 PM EST - 3 months ago

United Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 3:57 PM EST - 3 months ago

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

AAPL DT GLD ITRN MNKD NVDA OMC

Jan 5, 2026, 7:00 AM EST - 4 months ago

United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 7:19 AM EST - 5 months ago

Flurry of Bullish Inflows Sends United Therapeutics Higher

Nov 18, 2025, 7:00 AM EST - 5 months ago

United Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 9:30 AM EST - 6 months ago

United Therapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 4, 2025, 7:00 AM EST - 6 months ago

United Therapeutics Corporation to Present at Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 6 months ago

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease

Oct 29, 2025, 9:00 AM EDT - 6 months ago

United Therapeutics Earnings Call Transcript: Q3 2025

Oct 29, 2025, 6:30 AM EDT - 6 months ago

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results

Oct 15, 2025, 7:00 AM EDT - 7 months ago

United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

Oct 13, 2025, 7:00 AM EDT - 7 months ago

United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting

Sep 28, 2025, 12:30 PM EDT - 7 months ago

United Therapeutics Transcript: Study Update

Sep 23, 2025, 1:10 PM EDT - 7 months ago

United Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 19, 2025, 7:00 AM EDT - 7 months ago

United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis

Sep 16, 2025, 7:00 AM EDT - 8 months ago

United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum

Sep 12, 2025, 7:00 AM EDT - 8 months ago

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress

Sep 8, 2025, 3:20 PM EDT - 8 months ago

United Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 10:10 AM EDT - 8 months ago

United Therapeutics: Is UTHR Stock Still A Buy At $400?

Sep 2, 2025, 10:59 AM EDT - 8 months ago

Why Is United Therapeutics Stock Rallying On Tuesday?

Sep 2, 2025, 10:09 AM EDT - 8 months ago

United Therapeutics surges as Tyvaso succeeds in IPF trial: should you invest?

Sep 2, 2025, 9:17 AM EDT - 8 months ago

United Therapeutics shares surge on successful late-stage lung disease study

Sep 2, 2025, 7:00 AM EDT - 8 months ago

United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

Aug 29, 2025, 7:00 AM EDT - 8 months ago

United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 1, 2025, 7:00 AM EDT - 9 months ago

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

Jul 30, 2025, 9:00 AM EDT - 9 months ago

United Therapeutics Earnings Call Transcript: Q2 2025

Jul 30, 2025, 6:30 AM EDT - 9 months ago

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results

Jul 16, 2025, 7:00 AM EDT - 10 months ago

United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

Jun 24, 2025, 7:00 AM EDT - 11 months ago

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

Jun 23, 2025, 7:00 AM EDT - 11 months ago

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

Apr 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings Call Transcript: Q1 2025

Apr 30, 2025, 6:30 AM EDT - 1 year ago

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

Apr 21, 2025, 7:00 AM EDT - 1 year ago

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

Apr 4, 2025, 7:00 AM EDT - 1 year ago

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions

Mar 11, 2025, 10:00 AM EDT - 1 year ago

United Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

Mar 3, 2025, 1:50 PM EST - 1 year ago

United Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

United Therapeutics Earnings Call Transcript: Q4 2024

Feb 26, 2025, 6:30 AM EST - 1 year ago

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Feb 3, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial

Jan 21, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 13, 2025, 5:15 PM EST - 1 year ago

United Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 7:00 AM EST - 1 year ago

United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 7:00 AM EST - 1 year ago

United Therapeutics Announces Successful World's First UKidney Transplant

Nov 12, 2024, 5:45 PM EST - 1 year ago

United Therapeutics Transcript: UBS Global Healthcare Conference 2024

Oct 30, 2024, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings Call Transcript: Q3 2024

Sep 5, 2024, 8:00 AM EDT - 1 year ago

United Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 1:50 PM EDT - 1 year ago

United Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Jul 31, 2024, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings Call Transcript: Q2 2024

Jun 12, 2024, 4:00 PM EDT - 2 years ago

United Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 1, 2024, 9:00 AM EDT - 2 years ago

United Therapeutics Earnings Call Transcript: Q1 2024

Mar 12, 2024, 1:40 PM EDT - 2 years ago

United Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 5, 2024, 12:50 PM EST - 2 years ago

United Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 21, 2024, 9:00 AM EST - 2 years ago

United Therapeutics Earnings Call Transcript: Q4 2023

Jan 8, 2024, 2:15 PM EST - 2 years ago

United Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Nov 8, 2023, 10:00 AM EST - 2 years ago

United Therapeutics Transcript: UBS Biopharma Conference 2023

Nov 1, 2023, 9:00 AM EDT - 2 years ago

United Therapeutics Earnings Call Transcript: Q3 2023

Sep 11, 2023, 12:55 PM EDT - 2 years ago

United Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Aug 2, 2023, 9:00 AM EDT - 2 years ago

United Therapeutics Earnings Call Transcript: Q2 2023

May 3, 2023, 9:00 AM EDT - 3 years ago

United Therapeutics Earnings Call Transcript: Q1 2023

Mar 13, 2023, 11:30 AM EDT - 3 years ago

United Therapeutics Transcript: Oppenheimer Healthcare Conference

Feb 22, 2023, 9:00 AM EST - 3 years ago

United Therapeutics Earnings Call Transcript: Q4 2022

Jan 9, 2023, 4:30 PM EST - 3 years ago

United Therapeutics Transcript: JPMorgan Healthcare Conference

Nov 2, 2022, 10:00 AM EDT - 3 years ago

United Therapeutics Earnings Call Transcript: Q3 2022

Aug 3, 2022, 11:00 AM EDT - 4 years ago

United Therapeutics Earnings Call Transcript: Q2 2022

May 3, 2022, 8:00 PM EDT - 4 years ago

United Therapeutics Earnings Call Transcript: Q1 2022

Feb 23, 2022, 8:00 PM EST - 4 years ago

United Therapeutics Earnings Call Transcript: Q4 2021

Jan 6, 2022, 8:00 AM EST - 4 years ago

United Therapeutics Transcript: Fireside Chat

Nov 3, 2021, 4:00 AM EDT - 4 years ago

United Therapeutics Earnings Call Transcript: Q3 2021

Aug 4, 2021, 3:00 AM EDT - 5 years ago

United Therapeutics Earnings Call Transcript: Q2 2021

May 5, 2021, 3:00 AM EDT - 5 years ago

United Therapeutics Earnings Call Transcript: Q1 2021

Feb 24, 2021, 3:00 AM EST - 5 years ago

United Therapeutics Earnings Call Transcript: Q4 2020

Jan 19, 2021, 4:30 PM EST - 5 years ago

United Therapeutics Transcript: Study Result

Oct 28, 2020, 4:00 AM EDT - 5 years ago

United Therapeutics Earnings Call Transcript: Q3 2020

Jul 29, 2020, 3:00 AM EDT - 6 years ago

United Therapeutics Earnings Call Transcript: Q2 2020

Apr 29, 2020, 9:00 AM EDT - 6 years ago

United Therapeutics Earnings Call Transcript: Q1 2020

SuperGreenToday Apr. 30 at 7:54 PM

0 · Reply

stevemano Apr. 29 at 7:34 PM

$UTHR I hear Martin let Smokey mountain mist get into his eyes ! With the mist krap! https://youtu.be/HzckwQad9p4?si=XVBTBUw89wnXCs5k

0 · Reply

clan Apr. 29 at 6:50 PM

0 · Reply

clan Apr. 29 at 10:22 AM

0 · Reply

stevemano Apr. 29 at 9:43 AM

$MNKD perhaps this the $UTHR creature was in its form. Its day will come.

0 · Reply

grampslol Apr. 28 at 11:41 PM

I'm okay with $MNKD closing pennyland again...after all, it's Afizzle...lol $UTHR $SPY $BX $IBB

0 · Reply

DopeyCJ Apr. 28 at 7:32 PM

$BX $IBB $MNKD $UTHR what about being down more than 50% on the last 3 months?

1 · Reply

clan Apr. 28 at 7:28 PM

$MNKD I'm okay with MNKD being up over 20% in the last month. 🤑 More up and to the right coming.↗️ #pdufa #afrezza #autoinjector $BX $IBB $UTHR

0 · Reply

clan Apr. 28 at 2:42 PM

$MNKD RBC Capital certainly to upgrade and increase after FDA pediatric approval for Afrezza. #additionalindication #inflectionpoint #recordrevenues #cashgenerator $BX $UTHR $SPY

0 · Reply

grampslol Apr. 28 at 12:41 AM

0 · Reply

clan Apr. 28 at 12:34 AM

$UTHR When MNKD-1501 gets announced, $MNKD likely jumps $2/sh. #anydaynow #technosphere For the good of all mankind and Mannkind.

0 · Reply

clan Apr. 27 at 11:55 PM

$MNKD What if Unither $UTHR guides blockbuster Tyvaso DPI revenue growth over next 2+ years? What if $CIPLA.NSE reports better than expected initial Afrezza scripts, and additional orders, in India? What if the FDA approves Afrezza for kids ... early? What if we start seeing TV ads nationwide for Afrezza starting in June? What if Furoscix's sequential Q/Q sales grows > 20%? What if we see positive trial data for Nintedanib DPI? What if Unither announces the 2nd collaboration molecule? If most all of these happen, then on 7/7/26 this likely happens...

1 · Reply

grampslol Apr. 25 at 1:50 PM

$MNKD dpi has been rightfully called out by $UTHR martine for its dreadful coughing problems and with afrezza dpi being a flop of epic proportions martin/e is true that... #coughcough #blackboxinsulin #afizzle #pumperslie

0 · Reply

clan Apr. 25 at 12:29 PM

$MNKD $UTHR This has been, and remains, very important to Martine. #secondmolecule #lovesdpi #technosphere

0 · Reply

OfficialStocktwitsUser Apr. 25 at 3:41 AM

$UTHR RSI: 55.11, MACD: 10.7668 Vol: 14.40, MA20: 572.83, MA50: 534.74 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

JFais Apr. 24 at 1:43 PM

$LQDA- buyout on the cheap a real risk here IMO (due in part to perceived ongoing litigation risk with $UTHR) Would much rather give them 2+ years to build out PH-ILD (increasing diagnosis rates into 2030's now that there's a highly efficacious inhaled trepostinil) vs easy exit

2 · Reply

Pickin Apr. 21 at 9:02 AM

$MNKD so apparently there’s an upcoming ruling in the ongoing $LQDA and $UTHR lawsuit. I hope Martin gets his balls kicked in for treating his partner Mannkind like he did. I suppose he could be a eunuch so he might not get the full effect but let’s give it a try.

2 · Reply

Rolf1968 Apr. 18 at 9:57 AM

$UTHR ceo is a man confused that he is a woman.

0 · Reply

Bazzzigar Apr. 16 at 4:13 PM

$UTHR HIMS

1 · Reply

Quantumup Apr. 16 at 12:15 PM

Guggenheim⬆️ $INSM's to $230.00 and reiterated at Buy. $UTHR $LQDA MLTX INCY SLRN ABBV Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2044750606900846934?s=20

0 · Reply

grampslol Apr. 13 at 6:03 PM

$MNKD out of curiosity did $UTHR rothblatt report the DPI coughing issues to the FDA too or just to shareholders when she announced their future is with SMI treprostinil?... Also, won't Black Box Warning Label impede pending peds action from FDA?... Asking for a friend #afizzle #epicflop #coughcough

1 · Reply

phatsuit Apr. 8 at 1:53 PM

$UTHR ah huh

0 · Reply

Market Cap	25.03B
Revenue (ttm)	3.18B
Net Income (ttm)	1.33B
EPS (ttm)	N/A
PE Ratio	20.40
Forward PE	20.35
Profit Margin	41.94%
Debt to Equity Ratio	0.00

Volume	388,200
Avg Vol	577,636
Day's Range	N/A - N/A
Shares Out	43.83M
Stochastic %K	33%
Beta	0.75
Analysts	Strong Sell
Price Target	$647.15